• Explore /
  • Poster
  • / ARAMIS: Efficacy and safety of darolutamide in nonmetastatic castration-resistant prostate cancer (nmCRPC).

ARAMIS: Efficacy and safety of darolutamide in nonmetastatic castration-resistant prostate cancer (nmCRPC).

Abstract Poster

Authors

Karim Fizazi

Karim Fizazi

Gustave Roussy, University of Paris Sud, Villejuif, France

Karim Fizazi , Neal D. Shore , Teuvo Tammela , Albertas Ulys , Egils Vjaters , Sergey Polyakov , Mindaugas Jievaltas , Murilo Luz , Boris Y. Alekseev , Iris Kuss , Christian Kappeler , Amir Snapir , Toni Sarapohja , Matthew Raymond Smith

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Prostate Cancer

Track

Prostate Cancer,Prostate Cancer

Sub Track

Prostate Cancer - Advanced Disease

Clinical Trial Registration Number

NCT02200614

Citation

J Clin Oncol 37, 2019 (suppl 7S; abstr 140)

DOI

10.1200/JCO.2019.37.7_suppl.140

Abstract #

140

Poster Bd #

A4

Abstract Disclosures

Similar Posters

First Author: Tomasz M. Beer

First Author: Karim Fizazi

First Author: Matthew Raymond Smith

First Author: Karim Fizazi